CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm

Conditions

U07.1

Helena Stockmann, Philipp Thelen, Fabian Stroben, Mareen Pigorsch, Theresa Keller et al. (17 authors)

Critical Care Medicine2022-02-0970 citations

CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial.

Stockmann H, Keller T, Büttner S, Jörres A, Kindgen-Milles D, Kunz JV, Leebmann J, Spies C, Träger K, Treskatsch S, Uhrig A, Willam C, Enghard P, Slowinski T, CytoResc Trial Investigators.

2020-06-2620 citations

10.1186/s13063-020-04501-0

Interventions

Group 1: CytoSorb treatment initiated within 24 hours after fullfilling the inclusion criteria persued for 3-7 days Group 2: Standard of care without CytoSorb treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Males or females aged 18-80, Positive PCR test for SARS-CoV-2, Vasoplegic shock (Noradrenalin > 0.2 µg/min/kg (aiming MAD = 65mmHg), CRP > 100 mg/l, Indication for hemodialysis

Exclusion criteria

Exclusion criteria: Patients receiving Tocilizumab (anti-IL6-receptor antibody), Pregnancy

Design outcomes

Primary

Measure	Time frame
time to resolution of vasoplegic shock (defined as no need for vasopressors for at least 8 hours in order to sustain a MAD = 65mmHg) in days	—

Secondary

Measure	Time frame
7 day mortality after fulfilling the inclusion criteria, mortality until hospital discharge, IL-6 measurement on day 1 and 3, need for mechanical ventilation, duration of mechanical ventilation, duration of ICU-stay, catecholamine dose on day 1/2/3 after start of CytoSorb, acute kidney injury	—

Countries

Germany

Contacts

Public ContactLukas Johannes Lehner

Charité Campus Virchow-Klinikum

lukas.lehner@charite.de030+450-613559

Outcome results

None listed